RE:RE:Q&A?Was good, definitely geared towards the science and stayed mostly technical but some good tidbits in there for investors. Immunosuppression is a very important step and conformal coating going well preclinical brings all the pieces of the puzzle into the light. It might not be a short term catalyst but it sure supports the thesis that Sernova has what it takes for a functional cure and this will help in building valuation and securing a licensing deal.